Anti-inflammatory potential of the probiotic dietary supplement Lactibiane Tolerance:: In vitro and in vivo considerations

Background & aims: Probiotics are live microorganisms which when administered in adequate amounts confer a health benefit on the host. In inflammatory bowel disease (1131)), where major modifications of the intestinal microflora have been reported, there is an increasing interest in modulating the flora with probiotic products. This work addresses the anti-inflammatory potential of Lactibiane Tolerance, a probiotic dietary supplement (mixture of four strains) using in vitro and in vivo approaches. Methods: Comparison of the four individual strains and the commercial product reconstituted from them was conducted by in vitro tests (cytokine release after 24 h stimulation of human peripheral blood mononuclear cells (PBMC)). The potential immunomodulatory characteristics of Lactibiane Tolerance were determined in vivo in an acute mice model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. Assessment of colitis included blinded histological and macroscopic scores. Results: We showed that Lactibiane Tolerance has anti-inflammatory properties in vitro by stimulating IL-10 production and in vivo by conferring a significant protective effect in the TNBS-induced colitis model (more than 50% decrease of colitis symptoms, P < 0.01). Conclusions: These results demonstrate that a probiotic dietary supplement, Lactibiane Tolerance, can significantly prevent the initial injury of TNBS and could stimulate the initiation of clinical trials in IBD. (c) 2006 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.